Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study

PURPOSE: A large, randomized, double-blind, Phase III core study demonstrated that pasireotide LAR was significantly superior to octreotide LAR at providing GH <2.5 μg/L and normalized IGF-1 after 12 months’ treatment in patients with acromegaly. We report the efficacy and safety of pasireotide L...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheppard, Michael, Bronstein, Marcello D., Freda, Pamela, Serri, Omar, De Marinis, Laura, Naves, Luciana, Rozhinskaya, Liudmila, Hermosillo Reséndiz, Karina, Ruffin, Matthieu, Chen, YinMiao, Colao, Annamaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424273/
https://www.ncbi.nlm.nih.gov/pubmed/25103549
http://dx.doi.org/10.1007/s11102-014-0585-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424273/
https://www.ncbi.nlm.nih.gov/pubmed/25103549
http://dx.doi.org/10.1007/s11102-014-0585-6

Ejemplares similares